190 related articles for article (PubMed ID: 33533487)
1. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Graeser M; Schrading S; Gluz O; Strobel K; Würstlein R; Kümmel S; Schumacher C; Grischke EM; Forstbauer H; Braun M; Christgen M; Adams J; Nitzsche H; Just M; Fischer HH; Aktas B; Potenberg J; von Schumann R; Kolberg-Liedtke C; Harbeck N; Kuhl CK; Nitz U
Int J Cancer; 2021 May; 148(10):2614-2627. PubMed ID: 33533487
[TBL] [Abstract][Full Text] [Related]
2. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Graeser M; Harbeck N; Gluz O; Würstlein R; Zu Eulenburg C; Schumacher C; Grischke EM; Forstbauer H; Dimpfl M; Braun M; Christgen M; Kreipe HH; Potenberg J; von Schumann R; Aktas B; Kolberg-Liedtke C; Kümmel S; Nitz U
Breast; 2021 Oct; 59():58-66. PubMed ID: 34166854
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Graeser M; Schrading S; Gluz O; Strobel K; Herzog C; Umutlu L; Frydrychowicz A; Rjosk-Dendorfer D; Würstlein R; Culemann R; Eulenburg C; Adams J; Nitzsche H; Prange A; Kümmel S; Grischke EM; Forstbauer H; Braun M; Potenberg J; von Schumann R; Aktas B; Kolberg-Liedtke C; Harbeck N; Kuhl CK; Nitz U
Breast Cancer Res; 2021 Mar; 23(1):36. PubMed ID: 33736679
[TBL] [Abstract][Full Text] [Related]
4. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
[TBL] [Abstract][Full Text] [Related]
5. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
6. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
7. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
9. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
10. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
11. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
Murphy C; Mukaro V; Tobler R; Asher R; Gibbs E; West L; Giuffre B; Baron-Hay S; Khasraw M
Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790
[TBL] [Abstract][Full Text] [Related]
15. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response.
Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A
Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638
[TBL] [Abstract][Full Text] [Related]
18. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
19. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
Peterson JR; Cole JA; Pfeiffer JR; Norris GH; Zhang Y; Lopez-Ramos D; Pandey T; Biancalana M; Esslinger HR; Antony AK; Takiar V
Breast Cancer Res; 2023 May; 25(1):54. PubMed ID: 37165441
[TBL] [Abstract][Full Text] [Related]
20. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
